Global Pulmonary Arterial Hypertension (PAH) Market August 2016 | Page 4

Global Pulmonary Arterial Hypertension (PAH) Market (By Drug Class, By Region, By Country): Opportunities and Forecasts (2016-2021) (By Drug Class -Endothelin Receptor Antagonists, Prostacyclin & Prostacyclin Analogs, Phosphodiesterase V Inhibitors, Others; By Region-North America, Europe, APAC, Latin America, MEA; By Country- USA, Canada, UK, Germany, Japan, Brazil, South Africa) A comprehensive research report created through extensive primary research (inputs from industry experts, companies, stakeholders) and secondary research, the report aims to present the analysis of the global Pulmonary Arterial Hypertension (PAH) market on the basis of Drug Class (Endothelin Receptor Antagonists, Prostacyclin, Prostacyclin Analogs, Phosphodiesterase V Inhibitors, Others), By Region (North America, Europe, APAC, Latin America, MEA) and By Country (USA, Canada, UK, Germany, Japan, Brazil, South Africa). Also, the market for Pulmonary Arterial Hypertension (PAH) is growing moderately due to newer launches of pipeline drugs that target different pathways to supress the symptoms of the disease. Early diagnosis of the disease has played a pivotal role in number of patients undergoing treatment. Among the drug classes, the market is expected to be driven by ERAs. However, growing number of drugs under prostacyclin are expected to witness tremendous growth in the forecast period. Check for DISCOUNT at http://www.reportsnreports.com/contacts/discount.aspx?name=657034. Order this report by calling [phone] or Send an email to [email protected] with your contact details and questions if any. © ReportsnReports.com / Contact [email protected] 4